ClinicalTrials.gg
Not yet recruitingNCT07793578Updated Oct 5, 2026

Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer

A Phase 1/2 interventional study of capivasertib in Advanced Urothelial Carcinoma, sponsored by VA Office of Research and Development. Not yet recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by VA Office of Research and Development · Phase 1/2, Interventional, and Treatment

Updated Oct 5, 2026Start date movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to determine whether adding an oral medication called Capivasertib to ongoing immunotherapy can enhance treatment responses in patients with advanced bladder cancer (aBC), as well as to evaluate the safety of this combination. Capivasertib is an anti-cancer drug approved by the U.S. Food and Drug Administration (FDA) for breast cancer, but it is not approved for aBC and, in this study, will be used as an investigational agent. Immunotherapy is FDA-approved for aBC, yet while some patients respond, others either do not benefit or develop resistance after an initial response. Previous research indicates that drugs similar to Capivasertib may increase the effectiveness of immunotherapy. Therefore, this study will enroll patients whose aBC no longer responds to immunotherapy, add Capivasertib to their treatment regimen, and monitor for improvements in immune response against aBC and any potential side effects associated with the combination therapy.

Read the detailed description

This study will enroll patients with advanced bladder cancer who have previously received an immune checkpoint inhibitor (ICI) or ICI-based therapy and whose cancer is no longer responding to treatment. In this trial, patients will continue their ICI therapy while capivasertib is added to their regimen. Participants will be closely monitored to assess whether the addition of capivasertib enhances the cancer's response to ICI therapy and to evaluate the safety and potential toxicities of the combination treatment.

02

Conditions studied

  • Advanced Urothelial Carcinoma

Keywords

  • advanced urothelial carcinoma
  • immune checkpoint inhibitor
  • PI3K/AKT
  • capivaseretib
03

In context

Lead sponsor

VA Office of Research and Development is the lead sponsor of 1,773 studies on the registry; 393 are open to participants now.

Of its 213 completed or terminated interventional studies of FDA-regulated products, 185 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients are eligible
  2. Diagnosis of urothelial carcinoma, with mixed histology permitted:

    1. or cytologically confirmed advanced or recurrent urothelial carcinoma, OR
    2. Documented Stage IV disease (T4b, Any N, M0; any T, Any N, M1a-b), Stage IIIB (T1-T4a, N2-N3, M0), or a subset of Stage IIIA (T1-T4a, N1, M0)
  3. Genomic testing, including assessment for PIK3CA, AKT1, or PTEN alterations, must have been performed
  4. Patients must have stable disease or cancer progression after at least 12 weeks of (ICI) or ICI-based therapy, per v1.1 guidelines
  5. Patients must have received prior enfortumab vedotin unless
  6. Patients must be asymptomatic or minimally symptomatic from urothelial cancer
  7. Willingness to receive ICI in combination with capivasertib during the study is required. If cancer progressed on an ICI plus another anti-cancer drug(s) (e.g., pembrolizumab plus enfortumab vedotin), the additional drug(s) must be discontinued for at least 14 days, while ICI is continued, prior to starting capivasertib.
  8. Patients must have no or only minimal and stable adverse events from prior cancer-directed therapy, including ICI
  9. is required:

    1. X-rays, CT/MRI, or physical exams must have been performed within 28 days before starting study medications
    2. At least one measurable lesion per RECIST 1.1 must be present at baseline (≥10 mm in longest diameter, or lymph nodes with a short axis ≥15 mm, using CT or MRI; previously irradiated lesions are excluded)
  10. Tumor samples:

    1. Baseline prior to treatment is strongly recommended, unless it poses excessive risk
    2. When biopsied, in addition to FFPE preparation, fresh tissue should be sent to VABHS for single-cell RNA sequencing and T-cell receptor sequencing
    3. If baseline biopsy is not feasible, the most recent FFPE tumor tissue block from primary or metastatic sites should be obtained; if the block is unavailable, 15 (minimum 10) unstained slides are acceptable
    4. If biopsy is deemed too risky, participation may proceed without new tissue.
  11. Estimated of at least 3 months
  12. performance status ≤2 OR ≥60%. For the safety lead-in phase, only ECOG PS 0-1 patients will be included
  13. Adequate bone marrow function, without recent transfusions or growth factor support (within 14 days prior to first dose):

    1. > 1,000/cubic millimeters (mm³)
    2. ≥ 9.0 grams (g)/deciliter (dL)
    3. > 100,000/mm³
  14. Adequate renal function: Estimated ≥30 milliliter (mL)/minute (Cockcroft-Gault equation, actual weight), with no need for chronic dialysis. No capivasertib dose adjustment required if clearance ≥30 mL/minute
  15. Adequate liver function:

    1. Total ≤1.5 × value (ULN), or ≤3 × ULN for documented Gilbert's syndrome.
    2. and ALT ≤2.5 × ULN (or ≤5 × ULN for hepatic metastases).
  16. For females of : Negative serum pregnancy test at screening.
  17. Male patients able to father children, and females of childbearing potential, must agree to use two highly effective methods throughout the study and for at least 16 weeks after the last dose of capivasertib
  18. Signed and dated indicating the patient has been fully informed about the study
  19. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and all other study procedures

Exclusion criteria

Exclusion Criteria:

  1. Patients who have undergone major surgery within 4 weeks, or major radiation therapy within 2 weeks, prior to starting treatment. Prior palliative radiotherapy is permitted if completed at least 48 hours before study entry
  2. Receipt of another agent within the past 4 weeks. Participation in observational studies is allowed
  3. Persistent toxicities ( Grade ≥2) from previous anticancer therapy, except for alopecia. Patients with irreversible toxicity not reasonably expected to be exacerbated by study intervention (as deemed by the investigator, such as hearing loss) may be included.
  4. nausea and vomiting, chronic gastrointestinal disease, inability to swallow capivasertib, or prior significant bowel resection that may impair adequate absorption, distribution, metabolism, or excretion of capivasertib.
  5. Active tuberculosis infection, as determined by clinical evaluation, imaging, or tuberculosis testing per local practice
  6. Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor
  7. Known or suspected to study drugs or any of their components
  8. Spinal cord compression or , unless asymptomatic, stable, and not requiring for at least 4 weeks prior to study intervention. Patients with previously treated CNS metastases may be eligible if they have recovered from acute effects of radiation or surgery, discontinued corticosteroids for at least 4 weeks, and are neurologically stable
  9. Diagnosis of any other within the past 3 years, except adequately treated basal or squamous cell skin cancer, other Stage 0 or 1 cancers, or incidental prostate cancer found at cystoprostatectomy
  10. Moderate to severe symptoms from cancer, including moderate to severe pain, impaired organ function, or spinal cord compression
  11. Active disease likely to worsen with ICI therapy. Patients with vitiligo, psoriasis, or thyroid disorders controlled without therapy are eligible
  12. Known severe hypersensitivity reactions (Grade >3) to monoclonal antibodies, history of anaphylaxis, or uncontrolled asthma
  13. History or concurrent condition of interstitial lung disease or severely impaired lung function, as judged by the investigator
  14. Any of the following cardiac risks:

    1. Mean resting interval (QTc) >470 milliseconds (ms) from triplicate ECGs at screening
    2. History of QT prolongation due to medication requiring discontinuation
    3. Congenital long QT syndrome, family history of long QT, or unexplained sudden cardiac death under age 40 in first-degree relatives
    4. Significant arrhythmias (e.g., symptomatic or CTCAE Grade 3 PVCs, bigeminy, trigeminy, ventricular tachycardia), uncontrolled or symptomatic atrial fibrillation, unless well-controlled by medication or device (investigator and cardiologist review recommended)
    5. electrolyte abnormalities linked to QTc prolongation: hypokalemia, hypomagnesemia, hypocalcemia
    6. Any other condition(s) significantly increasing QTc prolongation risk per investigator judgment
    7. History of coronary artery bypass, angioplasty, myocardial infarction, or unstable angina in the prior 3 months
    8. Congestive heart failure ( class ≥2)
  15. Clinically significant abnormalities of glucose metabolism, including:

    1. Type 1 or insulin-dependent type 2 diabetes
    2. > 8.0%
  16. Current or prior use of immunosuppressive medications within 7 days before study start, except: a. Intranasal, inhaled, topical steroids, or local injections (e.g., intra-articular) b. Systemic corticosteroids up to 10 mg/day of prednisone or equivalent c. Steroids as premedication for hypersensitivity (e.g., CT scan premedication)
  17. Active bleeding diathesis.
  18. Active infection requiring systemic therapy.
  19. Positive for infection or known AIDS, due to potential pharmacokinetic interactions with capivasertib.
  20. (positive surface antigen) or (positive HCV RNA if antibody positive).
  21. Any other disease, condition, or laboratory abnormality which, in the investigator's opinion, may confound study results, increase the risks of study complications, contraindicate investigational drug use, or interfere with
  22. Vaccination with live, attenuated, or unknown-status vaccines within 4 weeks of first study treatment or during the trial (except inactivated vaccines, e.g., inactivated influenza and COVID-19 vaccines)
  23. Pregnancy, breastfeeding, or unwillingness/inability of female patients of and male patients to use two highly effective methods throughout the study and for at least 16 weeks after the last dose of capivasertib
  24. History of noncompliance with medical regimens
  25. Unwillingness or inability to comply with study protocol
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    treatment

    Patients will continue immune checkpoint inhibitor (ICI) treatment and capivasertib will be added

    Drug: capivasertib

Interventions

  • Patients will continue their immune checkpoint inhibitor (ICI) treatment, with capivasertib added at a dose of 400 mg orally twice daily, administered on a schedule of 4 days on followed by 3 days off, continuously throughout the study period.

    Also known as: Truqap

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the percentage of patients who have a partial or complete response at any time during the treatment of this trial.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Progression-free survival (PFS)

    PFS is defined as the time between initiation of the ICI/capivasertib combination treatment and tumor progression or death from any cause, with censoring of patients who are lost to follow-up

    Time frame: through study completion, an average of 1 year

  2. Overall survival (OS)

    OS is defined as the length of time from the start of this trial treatment to the time of death from any cause, with censoring of patients who are lost to follow-up.

    Time frame: through study completion, an average of 1.5 year

  3. Disease control rate (DCR)

    DCR is the percentage of patients who have a partial or complete response or stable disease at any time during this treatment of this trial.

    Time frame: through study completion, an average of 1 year

  4. Safety

    Safety will be determined by percentage of patients who develop adverse events (AEs) during the study. AEs will be graded on a 1-5 scale based on the Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: through study completion, an average of 1 year

  5. Tolerability

    Tolerability will be determined based on percentage of patients who have study drug dose reduction or discontinuation during the study secondary of adverse events.

    Time frame: through study completion, an average of 1 year

07

Study locations

4 sites
08

References and documents

Individual participant data

Plan to share: No — Aggregated data without any identifiable information will be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Sep 2029, 32 months later.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 28, 2026
StartEst.
Jan 1, 2027was Oct 2026
Primary completionEst.
Sep 30, 2029
CompletionEst.
Sep 30, 2030
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 1, 2027
Oct 5, 2026
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedSpinal cord compression or brain metastases, unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to study intervention. Patients with previously treated CNS metastases may be eligible if they have recovered from acute effects of radiation or surgery, discontinued corticosteroids for at least 4 weeks, and are neurologically stable
Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedobjectiveObjective response rate (ORR)Time frame: through study completion, an average of 1 year
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Start date Oct 1, 2026→Jan 1, 2027
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedSpinal cord compression or brain metastases, unless asymptomatic, stable, and not requiring steroids for at least 4 weeks prior to study intervention. Patients with previously treated CNS metastases may be eligible if they have recovered from acute effects of radiation or surgery, discontinued corticosteroids for at least 4 weeks, and are neurologically stable
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedobjectiveObjective response rate (ORR)Time frame: through study completion, an average of 1 year
    + 2 other changes: verification date and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07793578
Responsible party
Sponsor
First posted
Aug 28, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Sep 30, 2029 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Oct 5, 2026

Study contacts

Chong-Xian Pan, MD PhD
Contact
chong-xian.pan@va.gov
(857) 203-6189
Chun Yang, PhD
Contact
Chun.Yang@va.gov
(857) 736-5462
Chong-Xian Pan, MD PhD
principal investigator · VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capivasertib

Start the discussion